ASLAN Pharmaceuticals Stock (NASDAQ:ASLN)
Previous Close
$0.70
52W Range
$0.47 - $17.04
50D Avg
$1.07
200D Avg
$3.48
Market Cap
$1.70M
Avg Vol (3M)
$98.61K
Beta
1.40
Div Yield
-
ASLN Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
ASLN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| ACHL | Achilles Therapeutics plc |
| IVA | Inventiva S.A. |
| IOBT | IO Biotech, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| CTMX | CytomX Therapeutics, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| AGIO | Agios Pharmaceuticals, Inc. |
| GPCR | Structure Therapeutics Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| NLTX | Neurogene Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| TIL | Instil Bio, Inc. |
| CMPX | Compass Therapeutics, Inc. |